In vitro and in vivo Biological Evaluation of Newly Tacrine-Selegiline Hybrids as Multi-Target Inhibitors of Cholinesterases and Monoamine Oxidases for Alzheimer's Disease.

Published in: Drug design, development and therapy (2024)

could potentially serve as a promising multi-functional drug for the treatment of AD.

Keyphrases